ArticleFuture oncology (London, England)2025
Disease management landscape in patients with mantle cell lymphoma in Japan: a real-world study.
Article in Future oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimThe objective of this study was to describe the disease management landscape for patients with mantle cell lymphoma (MCL) in Japan.
methodsWe conducted a cross-sectional survey with retrospective data capture of physicians and their consulting patients between March and December 2022. Physicians completed patient record forms in a 1:2 ratio: one patient receiving first-line (1 L) treatment and two patients with relapsed/refractory disease, one of whom must have received and discontinued a Bruton's tyrosine kinase inhibitor (BTKi).
resultsSixty-seven patients were included - most were male (74.6%) and diagnosed with classical MCL (76.1%), with a mean age of 69.4 years and median time since MCL diagnosis of 18.0 months. The most common initial symptom was painless swelling in the neck, armpit, stomach, or groin (72%). Overall, patients had a "complete response" to 1 L (32/67 [47.8%]) therapy and "partial response" to 2 L (24/45 [53.3%]) therapy. Side effects were less commonly reported with BTKi than with chemotherapy. The most important physician-perceived treatment goal was to "minimize impact on patient's daily life" or "tumor response" for patients receiving BTKi or chemotherapy, respectively.
conclusionPatients' disease was generally well-managed by their physicians; however, improvements in efficacy, safety, and quality of life are still needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.